Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

4.70
+0.14503.19%
Post-market: 4.760.0650+1.38%17:39 EDT
Volume:862.65K
Turnover:4.05M
Market Cap:130.78M
PE:-3.01
High:4.81
Open:4.61
Low:4.57
Close:4.55
52wk High:8.74
52wk Low:3.93
Shares:27.86M
Float Shares:27.23M
Volume Ratio:0.89
T/O Rate:3.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.46
PE(LYR):-2.81

Loading ...

Unicycive Therapeutics Price Target Cut to $13.00/Share from $15.00 by HC Wainwright & Co.

Dow Jones
·
Sep 29

Unicycive Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $13 from $15

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics announces resubmission of NDA for OLC

TIPRANKS
·
Sep 29

Unicycive Resubmits FDA NDA for Oxylanthanum Carbonate Phosphate Binder

Reuters
·
Sep 29

Unicycive Therapeutics - FDA Acceptance of Nda Expected Within 30 Days; New Pdufa Date in 6 Months

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics - Nda Resubmission Includes Cmc Data from New Manufacturing Vendor

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics - FDA Inspection of Original Manufacturing Vendor Assigned but not Completed as of Sept 29, 2026

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics - Lawsuit Alleges Violations Related to Oxylanthanum Carbonate Phosphate Binder Statements - SEC Filing

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics - Securities Class Action Lawsuit Filed Against Unicycive Therapeutics and Certain Officers on Sept 3, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics Faces Securities Class Action Tied to Oxylanthanum Phosphate Binder NDA Statements

Reuters
·
Sep 29

Unicycive Therapeutics (UNCY) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Sep 22

Unicycive Therapeutics Faces Securities Lawsuit After 39% Stock Plunge Over Repeat FDA Manufacturing Setback

TIPRANKS
·
Sep 14

Unicycive Therapeutics Outlines Oxylanthanum Carbonate Program for Hyperphosphatemia in Dialysis Patients

Reuters
·
Sep 10

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 01

Unicycive Therapeutics price target raised to $15 from $13 at Benchmark

TIPRANKS
·
Aug 20

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

TIPRANKS
·
Aug 17

Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Drug Pipeline, Led by OLC for Dialysis Hyperphosphatemia

Reuters
·
Aug 17

Clene Q2 Net Loss Widens on Higher Other Expenses

Reuters
·
Aug 14